Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-5195

Pharmacological VTE prophylaxis-108v8 (eVTE-1)

XMLWordPrintable

    • Icon: Other Other
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Cynthia Indelicato
    • 631 444-4491
    • Stony Brook Medicine
    • Hide
      ​Thank you for your inquiry on VTE-1, Venous Thromboembolism Prophylaxis. Apixaban is contained within the following value set for the 2022 reporting period:

      "Medication, Administered: Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment" using "Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment (2.16.840.1.113883.3.117.1.7.1.134)"

      If you have additional questions, please let us know.
      Show
      ​Thank you for your inquiry on VTE-1, Venous Thromboembolism Prophylaxis. Apixaban is contained within the following value set for the 2022 reporting period: "Medication, Administered: Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment" using "Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment (2.16.840.1.113883.3.117.1.7.1.134)" If you have additional questions, please let us know.
    • CMS0108v10
    • Factor Xa Inhibitors, Rivaroxaban and Betrixaban, were the only medications added to Pharmacological VTE Prophylaxis code set.

      Do you know the rationale behind only adding two Factor Xa Inhibitors RIvaroxaban and Betrixaban) to pharmacological code set as an option to met VTE prophylaxis?
      FDA has approved Apixaban for VTE prophylaxis regardless of having AFib.

            JLeflore Mathematica EH eCQM Team
            cindelic Cynthia Indelicato
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: